Lumida
/BBIO
⌘K
BridgeBio Pharma Inc

BridgeBio Pharma Inc

BBIO
$72.44USD-0.08%-0.06 today

MARKET CAP

14.2B

P/E (TTM)

FWD P/E

DAY RANGE

$72 – $74

52W RANGE

$49
$93

AI Summary

Stalk
Buy NowMedium

BBIO is deeply oversold around its 200 DMA support after a sharp downtrend, and mean-reversion eligibility forces a medium-term bullish bias. Short-term price extension below declining EMAs at extreme OS levels suggests a tactical entry opportunity as price stabilizes near support, warranting a Buy Now execution on a pullback into this major structural zone.

  • Phase 3 acoramidis trial shows reversal of cardiac changes in ATTR-CM
  • Infigratinib Phase 3 PROPEL 3 trial positive in achondroplasia, NDA filing planned
  • Negative earnings yield and low book-to-price signal possible overvaluation
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$69.7M$77.6M$9.3M$221.9M$502.1M
YoY %+745.1%+11.4%-88.0%+2285.3%+126.3%
P / Sales34.5x13.6x707.8x23.0x29.2x
EV / Sales55.8x32.8x870.5x30.7x34.0x
Gross Profit, Adj.$66.6M$74.2M$6.9M$218.0M$481.1M
YoY %+707.4%+11.4%-90.8%+3079.6%+120.7%
Margin %95.5%95.6%73.7%98.3%95.8%
EV / Gross Profit58.4x34.3x1181.0x31.2x35.5x
EBITDA, Adj.$-570.8M$-461.7M$-593.0M$-571.3M$-496.6M
YoY %-20.7%+19.1%-28.4%+3.7%+13.1%
Margin %-818.7%-594.6%-6373.8%-257.5%-98.9%
EV / EBITDA-6.8x-5.5x-13.7x-11.9x-34.4x
EBIT$-576.6M$-512.2M$-607.4M$-593.0M$-523.4M
YoY %-21.5%+11.2%-18.6%+2.4%+11.7%
Margin %-827.1%-659.6%-6528.8%-267.2%-104.2%
EV / EBIT-6.8x-5.0x-13.3x-11.5x-32.7x
Net Income$-562.5M$-481.2M$-643.2M$-535.8M$-724.9M
YoY %-25.4%+14.5%-33.7%+16.7%-35.3%
Net Margin-806.9%-619.7%-6913.9%-241.4%-144.4%
EPS (GAAP)-$3.90-$3.26-$3.95-$2.88-$3.78
YoY %-2.6%+16.4%-21.2%+27.1%-31.3%